Details:
Sedaconda (isoflurane), a general inhalation anesthetic, acts as a positive allosteric GABAA receptor modulator. It enhances glycine receptor activity, which decreases motor function and inhibits NMDA glutamate receptor, which mediates excitatory neurotransmission activity.
Lead Product(s): Isoflurane
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2023
Details:
BAN2401 (lecanemab), an investigational humanized monoclonal antibody, selectively binds to, neutralize and eliminate soluble toxic Aβ aggregates (protofibrils) that are thought to contribute to the neurodegenerative process in AD.
Lead Product(s): Lecanemab
Therapeutic Area: Neurology Product Name: BAN2401
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Eisai
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 11, 2022
Details:
Sedaconda (isoflurane) for inhaled sedation used in combination with medical device Sedaconda ACD, it's primary endpoint in each study will is effective and non-inferior to propofol for sedation of mechanically ventilated patients in the intensive care unit.
Lead Product(s): Isoflurane
Therapeutic Area: Neurology Product Name: Sedaconda
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 24, 2021
Details:
Lecanemab selectively binds to, neutralize and eliminate soluble toxic Aβ aggregates (protofibrils) that are thought to contribute to the neurodegenerative process in AD.
Lead Product(s): Lecanemab
Therapeutic Area: Neurology Product Name: BAN2401
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2021
Details:
The presentations will include the latest data of the investigational anti-amyloid beta (Aβ) protofibril selective antibody lecanemab (BAN2401) for which the FDA has granted Breakthrough Therapy designation.
Lead Product(s): Lecanemab
Therapeutic Area: Neurology Product Name: BAN2401
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Eisai
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2021
Details:
The topline results, announced in July 2020, showed that the study reached its primary goal; to show that Sedaconda administered via AnaConDa is an effective sedation method for ventilated ICU patients, comparable to propofol.
Lead Product(s): Isoflurane
Therapeutic Area: Neurology Product Name: Sedaconda
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2021
Details:
The proof-of-concept Study 201 explored the impact of treatment with lecanemab on reducing brain amyloid beta. In this study, pre-specified analysis showed consistent reduction of clinical decline across several clinical and biomarker endpoints at the highest doses.
Lead Product(s): Lecanemab
Therapeutic Area: Neurology Product Name: BAN2401
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Eisai
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2021
Details:
The manuscript describes results from Study 201, a Phase 2b proof-of-concept study that explored the impact of treatment with lecanemab on reducing brain amyloid beta (Aβ) and clinical decline in patients with early Alzheimer's disease.
Lead Product(s): Lecanemab
Therapeutic Area: Neurology Product Name: BAN2401
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2021
Details:
The results indicate that IsoConDa is an effective and safe sedation method and will form the basis for the company's application for European market approval later this autumn.
Lead Product(s): Isoflurane
Therapeutic Area: Neurology Product Name: IsoConDa
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 10, 2020
Details:
The enrollment of patients with early Alzheimer's disease will be carried out at memory clinics at four Swedish university hospitals.
Lead Product(s): Ban2401
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 03, 2020